Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLU-5937 in Refractory Chronic Cough (CALM-2)
NCT05600777Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Dec 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of camlipixant in refractory chronic cough (RCC) (3 arms), sponsored by GSK. Primary endpoints: 24-Hour Cough Frequency at 24 weeks, Number of Participants with Adverse Events and Serious Adverse Events at 24 weeks and 8 more. Started Dec 2022; status: active, not recruiting.
02
Drugs
camlipixant
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on NCT05600777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05600777.